Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1708 ARTÍCULOS , VIENDO DEL 196 AL 210

Sleep and Attention in Alzheimer's Disease

Hennawy M, Sabovich S, Liu CS, Herrmann N, Lanctôt KL.

Yale J Biol Med. 2019 Mar 25;92(1):53-61. eCollection 2019 Mar.

Therapeutic targeting of nuclear receptors, liver X and retinoid X receptors, for Alzheimer's disease

Fitz NF, Nam KN, Koldamova R, Lefterov I.

Br J Pharmacol. 2019 Sep;176(18):3599-3610. doi: 10.1111/bph.14668. Epub 2019 May 11.

Current and Future Treatments in Alzheimer's Disease

Atri A.

Semin Neurol. 2019 Apr;39(2):227-240. doi: 10.1055/s-0039-1678581. Epub 2019 Mar 29.

Neuroimmune Crosstalk through Extracellular Vesicles in Health and Disease

Delpech JC, Herron S, Botros MB, Ikezu T.

Trends Neurosci. 2019 May;42(5):361-372. doi: 10.1016/j.tins.2019.02.007. Epub 2019 Mar 26.

Understanding the link between insulin resistance and Alzheimer's disease: Insights from animal models

Lyra E Silva NM, Gonçalves RA, Boehnke SE, Forny-Germano L, Munoz DP, De Felice FG.

Exp Neurol. 2019 Jun;316:1-11. doi: 10.1016/j.expneurol.2019.03.016. Epub 2019 Mar 28.

The Potential Influence of Bone-Derived Modulators on the Progression of Alzheimer's Disease

Yuan J, Meloni BP, Shi T, Bonser A, Papadimitriou JM, Mastaglia FL, Zhang C, Zheng M, Gao J.

J Alzheimers Dis. 2019;69(1):59-70. doi: 10.3233/JAD-181249.

Molecular Basis of Alzheimer's Disease: Focus on Mitochondria

Oliver DMA, Reddy PH.

J Alzheimers Dis. 2019;72(s1):S95-S116. doi: 10.3233/JAD-190048.

Transition Metal Ion Interactions with Disordered Amyloid-β Peptides in the Pathogenesis of Alzheimer's Disease: Insights from Computational Chemistry Studies

Strodel B, Coskuner-Weber O.

J Chem Inf Model. 2019 May 28;59(5):1782-1805. doi: 10.1021/acs.jcim.8b00983. Epub 2019 Apr 15.

Ginkgo biloba Extract (EGb761), Cholinesterase Inhibitors, and Memantine for the Treatment of Mild-to-Moderate Alzheimer's Disease: A Network Meta-Analysis

Thancharoen O, Limwattananon C, Waleekhachonloet O, Rattanachotphanit T, Limwattananon P, Limpawattana P.

Drugs Aging. 2019 May;36(5):435-452. doi: 10.1007/s40266-019-00648-x.

Platelet-generated amyloid beta peptides in Alzheimer's disease and glaucoma

Inyushin M, Zayas-Santiago A, Rojas L, Kucheryavykh Y, Kucheryavykh L.

Histol Histopathol. 2019 Aug;34(8):843-856. doi: 10.14670/HH-18-111. Epub 2019 Apr 4.

Race reporting and disparities in clinical trials on Alzheimer's disease: A systematic review

Canevelli M, Bruno G, Grande G, Quarata F, Raganato R, Remiddi F, Valletta M, Zaccaria V, Vanacore N, Cesari M.

Neurosci Biobehav Rev. 2019 Jun;101:122-128. doi: 10.1016/j.neubiorev.2019.03.020. Epub 2019 Apr 1.

Pharmacokinetic Characterizations of Ginsenoside Ocotillol, RT5 and F11, the Promising Agents for Alzheimer's Disease from American Ginseng, in Rats and Beagle Dogs

Li Y, Hu H, Li Z, Li R, Xu F, Zhao C, An Y, Liu Y, Wang Z, Zhang B, Geng C.

Pharmacology. 2019;104(1-2):7-20. doi: 10.1159/000499595. Epub 2019 Apr 4.

Current Updates on the Regulation of Beta-Secretase Movement as a Potential Restorative Focus for Management of Alzheimer's Disease

Ahmad SS, Kamal MA.

Protein Pept Lett. 2019;26(8):579-587. doi: 10.2174/0929866526666190405125334.

Naproxen for presymptomatic Alzheimer disease: Is this the end, or shall we try again?

Hershey LA, Lipton RB.

Neurology. 2019 Apr 30;92(18):829-830. doi: 10.1212/WNL.0000000000007233. Epub 2019 Apr 5.

INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease

Meyer PF, Tremblay-Mercier J, Leoutsakos J, Madjar C, Lafaille-Magnan ME, Savard M, Rosa-Neto P, Poirier J, Etienne P, Breitner J; PREVENT-AD Research Group.

Neurology. 2019 Apr 30;92(18):e2070-e2080. doi: 10.1212/WNL.0000000000007232. Epub 2019 Apr 5.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias